This is not the most recent version of the article. View current version (18 JAN 2012)

Intervention Review

You have free access to this content

Steroids for acute spinal cord injury

  1. Michael B Bracken*

Editorial Group: Cochrane Injuries Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 19 SEP 2007

DOI: 10.1002/14651858.CD001046

Database Title

Additional Information

How to Cite

Bracken MB. Steroids for acute spinal cord injury. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001046. DOI: 10.1002/14651858.CD001046.

Author Information

  1. Yale University Medical School, Department of Epidemiology & Public Health, New Haven, CT, USA

*Michael B Bracken, Department of Epidemiology & Public Health, Yale University Medical School, Box 20834, 60 College Street, New Haven, CT, 06520-8034, USA. michael.bracken@yale.edu.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (18 Jan 2012)

View Full Article (HTML) Summary (56K)Standard (229K)Full (474K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 2 Motor function at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 7 All-cause mortality, <210 days.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 8 Wound infection at six weeks.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 9 GI haemorrhage at six weeks.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 10 Sepsis at six weeks.
[Analysis 2.1]
Analysis 2.1. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 2.2]
Analysis 2.2. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 2 Motor function at six weeks, six months, and one year: <8 hours to treatment.
[Analysis 2.3]
Analysis 2.3. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 2.4]
Analysis 2.4. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 2.5]
Analysis 2.5. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 5 Touch sensation at six weeks, six months and one year: All patients.
[Analysis 2.6]
Analysis 2.6. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 2.7]
Analysis 2.7. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 7 All-cause mortality <180 days.
[Analysis 2.8]
Analysis 2.8. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 8 Wound infection at 6 weeks.
[Analysis 2.9]
Analysis 2.9. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 9 GI haemorrhage at 6 weeks.
[Analysis 3.1]
Analysis 3.1. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 3.2]
Analysis 3.2. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 2 Motor function at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.3]
Analysis 3.3. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 3.4]
Analysis 3.4. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 4 Pinprick sensation at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.5]
Analysis 3.5. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.
[Analysis 3.6]
Analysis 3.6. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 6 Touch sensation at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.7]
Analysis 3.7. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 7 Severe pneumonia at 6 weeks.
[Analysis 3.8]
Analysis 3.8. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 8 Severe sepsis at 6 weeks.
[Analysis 3.9]
Analysis 3.9. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 9 Mortality at 1 year.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 1 One-year motor function improvement score.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 2 One-year pinprick sensation improvement score.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 3 One-year touch sensation improvement score.
View Full Article (HTML) Summary (56K)Standard (229K)Full (474K)